These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8836622)

  • 1. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors.
    Gatley SJ; Gifford AN; Volkow ND; Lan R; Makriyannis A
    Eur J Pharmacol; 1996 Jul; 307(3):331-8. PubMed ID: 8836622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors.
    Gatley SJ; Lan R; Pyatt B; Gifford AN; Volkow ND; Makriyannis A
    Life Sci; 1997; 61(14):PL 191-7. PubMed ID: 9335234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
    J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.
    Gatley SJ; Lan R; Volkow ND; Pappas N; King P; Wong CT; Gifford AN; Pyatt B; Dewey SL; Makriyannis A
    J Neurochem; 1998 Jan; 70(1):417-23. PubMed ID: 9422389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
    Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
    Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand.
    Lan R; Gatley J; Lu Q; Fan P; Fernando SR; Volkow ND; Pertwee R; Makriyannis A
    AAPS PharmSci; 1999; 1(2):E4. PubMed ID: 11741201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.
    Fride E; Ginzburg Y; Breuer A; Bisogno T; Di Marzo V; Mechoulam R
    Eur J Pharmacol; 2001 May; 419(2-3):207-14. PubMed ID: 11426843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
    Craft RM; Wakley AA; Tsutsui KT; Laggart JD
    J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large receptor reserve for cannabinoid actions in the central nervous system.
    Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
    J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
    Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
    J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
    Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F; Jeantaud B; Capet M; Doble A
    Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.
    Rinaldi-Carmona M; Barth F; Héaulme M; Alonso R; Shire D; Congy C; Soubrié P; Brelière JC; Le Fur G
    Life Sci; 1995; 56(23-24):1941-7. PubMed ID: 7776817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further evidence for the presence of cannabinoid CB1 receptors in mouse vas deferens.
    Pertwee RG; Joe-Adigwe G; Hawksworth GM
    Eur J Pharmacol; 1996 Jan; 296(2):169-72. PubMed ID: 8838453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands.
    Zhang Q; Ma P; Wang W; Cole RB; Wang G
    Drug Metab Dispos; 2005 Apr; 33(4):508-17. PubMed ID: 15616153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM; Martin BR
    Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
    Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
    Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
    Maneuf YP; Nash JE; Crossman AR; Brotchie JM
    Eur J Pharmacol; 1996 Jul; 308(2):161-4. PubMed ID: 8840127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist.
    Hirst RA; Almond SL; Lambert DG
    Neurosci Lett; 1996 Dec; 220(2):101-4. PubMed ID: 8981483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.